Core Viewpoint - Guardian Pharmacy Services (GRDN) is expected to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show quarterly earnings of $0.24 per share, reflecting a +112% change year-over-year, and revenues are projected to be $353.95 million, up 12.6% from the previous year [3]. - The earnings report is scheduled for November 10, and stock movement may depend on whether the actual results exceed or fall short of these expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised 2.04% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for Guardian Pharmacy is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.82%, suggesting a bearish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Guardian Pharmacy was expected to post earnings of $0.22 per share but delivered $0.23, resulting in a surprise of +4.55% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Comparison - Nektar Therapeutics (NKTR), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $2.85 per share, indicating a year-over-year change of -5.6%, with revenues expected to decline by 56.1% [18][19]. - Nektar's consensus EPS estimate has been revised 2.6% higher recently, and it has a positive Earnings ESP of +18.72%, combined with a Zacks Rank of 2 (Buy), indicating a likely earnings beat [19][20].

Core Viewpoint - Cass Information Systems (CASS) is anticipated to report a year-over-year increase in earnings despite a decline in revenues for the quarter ended September 2025, with the consensus outlook indicating a significant earnings picture that could influence its stock price in the near term [1][3]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.63 per share, reflecting a year-over-year increase of +200%, while revenues are projected to be $49.4 million, down 2.3% from the previous year [3]. - The consensus EPS estimate has been revised 1.54% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, indicating no recent differing analyst views [12]. - The stock currently holds a Zacks Rank of 5, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Cass was expected to post earnings of $0.72 per share but only achieved $0.38, resulting in a surprise of -47.22% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Investment Considerations - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [15]. - While Cass does not appear to be a strong candidate for an earnings beat, investors should consider additional factors before making investment decisions [17].

Group 1 - PENN Entertainment is expected to report a year-over-year increase in earnings, with a projected quarterly loss of $0.04 per share, reflecting a change of +77.8% [3][12] - Revenues for PENN are anticipated to be $1.73 billion, which is a 4.3% increase from the same quarter last year [3] - The consensus EPS estimate has been revised 8.61% lower over the last 30 days, indicating a reassessment by analysts [4] Group 2 - The Zacks Earnings ESP for PENN is +23.32%, suggesting a bullish outlook from analysts regarding the company's earnings prospects [12] - The stock currently holds a Zacks Rank of 3, indicating a hold position [12] - Historically, PENN has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +13.79% [13][14] Group 3 - Super Group (SGHC) Limited, another player in the gaming industry, is expected to report earnings per share of $0.13, representing a year-over-year change of +62.5% [18] - Revenues for Super Group are projected to be $503 million, up 12.7% from the previous year [18] - The consensus EPS estimate for Super Group has been revised 16.7% lower over the last 30 days, with an Earnings ESP of 0% [19]

Company Overview - Progyny (PGNY) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.44, reflecting a change of +2.3% [3] - Revenues are anticipated to reach $322.5 million, representing a 6.1% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 4.08% over the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +0.92% suggests that analysts have recently become more optimistic about Progyny's earnings prospects [12] Historical Performance - Progyny has consistently beaten consensus EPS estimates, achieving this in the last four quarters [14] - In the most recent quarter, Progyny exceeded expectations by delivering earnings of $0.48 per share against an expected $0.45, resulting in a surprise of +6.67% [13] Market Sentiment - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [2] - The combination of a positive Earnings ESP and a Zacks Rank of 3 indicates a likelihood of beating the consensus EPS estimate [12]

Company Overview - Sempra (SRE) is anticipated to report a year-over-year decline in earnings, with expected earnings of $0.83 per share, reflecting a decrease of 6.7% compared to the previous year [3][12] - The company's revenues are projected to be $3.15 billion, which represents an increase of 4.7% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on August 7, and the actual results will significantly influence the stock price, depending on whether they meet or exceed expectations [2][12] - The consensus EPS estimate has been revised 8.84% higher in the last 30 days, indicating a more optimistic outlook from analysts [4] Earnings Surprise Prediction - Sempra has an Earnings ESP (Expected Surprise Prediction) of +0.60%, suggesting a likelihood of beating the consensus EPS estimate [12] - The company currently holds a Zacks Rank of 2 (Buy), which, when combined with a positive Earnings ESP, indicates a strong potential for an earnings beat [10][12] Historical Performance - In the last reported quarter, Sempra exceeded the expected earnings of $1.21 per share by delivering $1.44, resulting in a surprise of +19.01% [13] - Over the past four quarters, Sempra has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Utility - Gas Distribution industry, Atmos Energy (ATO) is expected to report earnings of $1.17 per share, reflecting a year-over-year increase of 8.3% [18] - Atmos Energy's revenue is projected to be $940.91 million, up 34.1% from the previous year [18] - Despite a recent downward revision of 3.4% in the consensus EPS estimate for Atmos, it has a Zacks Rank of 3 (Hold) and an Earnings ESP of 0%, making predictions about its performance less conclusive [19]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Airbnb, Inc. driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected on August 6, with a consensus EPS estimate of $0.93, reflecting an 8.1% year-over-year increase, and revenues projected at $3.03 billion, a 10.3% increase from the previous year [3][12]. - The consensus EPS estimate has been revised 0.33% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +3.78% for Airbnb, suggesting a likelihood of beating the consensus EPS estimate [12]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, which increases the predictive power of the Earnings ESP [10]. Historical Performance - In the last reported quarter, Airbnb was expected to post earnings of $0.25 per share but delivered $0.24, resulting in a -4.00% surprise [13]. - Over the last four quarters, Airbnb has only beaten consensus EPS estimates once [14]. Conclusion - While Airbnb is positioned as a compelling earnings-beat candidate, other factors may influence stock movement beyond just earnings results [15][17].

Company Overview - Dutch Bros (BROS) is anticipated to report a year-over-year decline in earnings of -5.3%, with expected earnings of $0.18 per share for the quarter ended June 2025 [3][12] - Revenue is projected to be $401.94 million, reflecting a significant increase of 23.7% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 1.08% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Dutch Bros is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +1.62%, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Dutch Bros exceeded the expected earnings of $0.10 per share by delivering $0.14, resulting in a surprise of +40.00% [13] - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14] Industry Context - The Zacks Retail - Restaurants industry includes other players like First Watch Restaurant Group, which is expected to post earnings of $0.07 per share, indicating a year-over-year decline of -50% [18] - First Watch's revenue is expected to be $305.97 million, up 18.3% from the previous year, but it has a negative Earnings ESP of -28.57%, making it challenging to predict an earnings beat [19][20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings and revenues for Civitas Resources in the upcoming earnings report, with actual results being crucial for stock price movement [1][3]. Earnings Expectations - Civitas is expected to report quarterly earnings of $1.17 per share, reflecting a year-over-year decrease of 43.2% [3]. - Revenues are projected to be $1.14 billion, down 13.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.84% higher in the last 30 days, indicating a reassessment by analysts [4]. - Civitas has a negative Earnings ESP of -3.99%, suggesting recent bearish sentiment among analysts regarding the company's earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [9][10]. - Civitas currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Civitas exceeded earnings expectations with a surprise of +5.36% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - Civitas does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of the earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Tango Therapeutics, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Tango Therapeutics is expected to report a quarterly loss of $0.35 per share, reflecting a year-over-year change of -45.8% [3]. - Revenues are projected to be $6.19 million, down 68.9% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.62% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Tango Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.57% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Tango Therapeutics currently holds a Zacks Rank of 2, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.34 per share but actually reported a loss of -$0.36, resulting in a surprise of -5.88% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Krystal Biotech, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $1.08 for the same quarter, indicating a year-over-year change of +25.6% [18]. - Revenues for Krystal Biotech are expected to be $90.5 million, up 28.8% from the previous year [18].

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with the actual results having a significant impact on its near-term stock price [1][2]. Financial Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.03 per share, reflecting a year-over-year increase of 150% [3]. - Revenues are projected to be $148.85 million, which is a 36.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly reassessed their initial estimates [4]. - For BioCryst, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -66.67%, suggesting a bearish outlook from analysts [11]. Earnings Surprise History - In the last reported quarter, BioCryst was expected to post a loss of $0.07 per share but instead delivered break-even earnings, resulting in a surprise of +100.00% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - In the Zacks Medical - Drugs industry, Indivior PLC (INDV) is expected to report earnings of $0.26 per share for the same quarter, indicating a year-over-year decline of 40.9% [17]. - Indivior's revenue is projected to be $244.27 million, down 18.3% from the previous year, but it has an Earnings ESP of +11.54%, suggesting a likelihood of beating the consensus EPS estimate [18][19].